Dutch vaccine development company Mucosis B.V. announced today that it has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clinical development of its lead product FluGEM™, an influenza vaccine that can be administered by a simple spray in the nose. The loan will be redeemed only if the FluGEM™ clinical development program is concluded successfully.
“We are really pleased with the government’s financial support. This non-dilutive funding underlines the progress we have made so far and, even more importantly, strengthens our financial capabilities going forward. It will enable us to generate proof of efficacy with FluGEM™ in man” said Govert Schouten, CEO of Mucosis.
Mucosis develops novel vaccines on the basis of its unique Mimopath™ technology. This invention is key to the growth strategy for the coming years.